
The acquisition brings Gallant’s experimental stem cell treatments for feline chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
Here is a sneak peek at this week’s headlines.
Happy Monday! We have a lot of engaging and informative content coming your way. Here's a quick at some of this week's headlines:
Stay tuned on dvm360.com for our most recent coverage of the veterinary industry.




